Vasodilator agents protect against indinavir nephrotoxicity

Antiviral Therapy

Volumn 8, Issue 4, 2003, Pages 295-299

  De Araujo, Magali ^a,b   Seguro, Antonio Carlos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CALCIUM CHANNEL; CITRIC ACID; CREATININE; INDINAVIR; MAGNESIUM CHLORIDE; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NITRITE; NITROGEN DIOXIDE; NITROUS OXIDE; VASODILATOR AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DRUG CLEARANCE; GLOMERULUS FILTRATION RATE; KIDNEY ARTERY VASOCONSTRICTION; KIDNEY BLOOD FLOW; MAGNESIUM BLOOD LEVEL; MAGNESIUM DEFICIENCY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

EID: 0042324107     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.1177/135965350300800405     Document Type: Article

References (29)

1. Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan ERN, Baker C, Pannel LK & Falcoon J. Crystalluria and urinary tract abnormalities associated with indinavir. Annals of Internal Medicine 1997; 127(2):119-125.
2. Gagnon RF, Tecimer SN, Watters AK & Tsoukas CM. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. American Journal of Kidney Diseases 2000; 36(3):507-515.
3. Perazella MA. Cristal-induced acute renal failure. American Journal of Medicine 1999; 106:459-465.
4. Jaradat M, Phillips C, Yun MN, Cushing H & Moe S. Acute tubulointerstitial nephritis attributable to indinavir therapy. American Journal of Kidney Diseases 2000; 35(4):E16.
5. Cattelan AM, Trevenzoli M, Naso A, Meneghetti F & Cadrobbi P. Severe hypertension and renal atrophy associated with indinavir. Clinical Infectious Diseases 2000; 30:619-621.
6. Boubaker K, Sudre P, Bally F, Vogel G, Meuwly JY, Gauser MP & Telenti A. Changes in renal function associated with indinavir. AIDS 1998; 12(18):F249-F254.
7. Van Rossum AMN, Dieleman JP, Fraaij PLA, Cransberg K, Hartwig NG, Burger DM, Gyssens IC & de Groot R. Persistent leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children with indinavir. Pediatrics 2002; 110(2):e19.
8. Araujo M & Seguro AC. Trimethoprim-sulfamethoxazole (TMP-SMX) potentiates indinavir nephrotoxicity. Antiviral Therapy 2002; 7:181-184.
9. Assis SM, Monteiro JL & Seguro AC. L-arginine and allopurinol protect against cyclosporine nephrotoxicity. Transplantation 1997; 63(8):1070-1073.
10. Andrade L, Campos SB & Seguro AC. Hypercholesterolemia aggravates radiocontrast nephrotoxicity: Protective role of L-arginine. Kidney International 1998; 53:1736-1742.
11. Moncada S, Palmer RM & Higgs EA. Nitric oxide; physiology, pathophysiology, and pharmacology. Pharmacological Reviews 1991; 43:109-142.
12. Böger RH & Bode-Böger SM. The clinical pharmacology of L-arginine. Annual Review of Pharmacology & Toxicology 2001; 41:79-99.
13. Weis M, Pehlivanli S & von Scheidt W. Vasodilator response to nifedipine in human coronary arteries with endothelial dysfunction. Journal of Cardiovascular Pharmacology 2002; 39:172-180.
14. Frielingsdorf J, Seiler C, Kaufmann P, Vassalli G, Suter T & Hess OM. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996; 93:1380-1387.
15. Dacey MJ. Hypomagnesemic disorders. Critical Care Clinics 2001; 17:155-173.
16. Agus MSD & Agus ZS. Cardiovascular actions of magnesium. Critical Care Clinics 2001; 17:175-186.
17. Gabbai FB & Blantz RC. Role of nitric oxide in renal hemodynamics. Seminars in Nephrology 1999; 19:242-250.
18. Lekakis JP, Papathanassiou S, Papaioannou TG, Papamichael CM, Zakopoulos N, Kotsis V, Dagre AG, Stamatelopoulos K, Protogerou A & Stametolopoulos SF. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. International Journal of Cardiology 2002; 86:317-323.
19. Huynh NT & Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. Journal of the American College of Nutrition 2002; 21:422-427.
20. Schramm L, La M, Heidbreder E, Hecker M, beckman JS, Lopau K, Zimmermann J, Rendl J, Reiners C, Winderl S, Wanner C & Schmidt H. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney International 2002; 61:1423-1432.
21. Nakamura M, Arakawa N, Yoshida H, Naganuma Y, Nagano M & Hiramori K. Nitric oxide plays an insignificant role in direct vaodilator effets of calcium channel blockers in healthy humans. Heart Vessel 2002; 16:105-110.
22. Sánchez-Lozada LG, Gamba G, Bolio A, Jimémez F, Herrera-Acosta J & Bobadilla NA. Nifedipine prevents changes in nitric oxide synthase mRNA levels induced by cyclosporine. Hypertension 2000; 36:624-647.
23. 2+-channels markedlv diminishes nitric oxide- but not L-S-nitrocysteine-or endothelium-dependent vasodilation in vivo. European Journal of Pharmacology 2000; 408:289-298.
24. Berkels R, Egink G, Marsen TA, Bartels H, Roesen R & Klaus W. Nifedipine increases endotelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37:240-245.
25. 2+ induced endothelium-dependent relaxation of blood vessels and blood pressure lowering: role of NO. American Journal of Physiology Regulatory Integrative Comparative Physiology 2000; 278:R628-R639.
26. Teragawa H, Kato M, Yamagata T, Matsuura H & Kajiyama G. Magnesium causes nitric oxide independent coronary artery vasodilation in humans. Heart 2001; 86:212-216.
27. Fandrey J, Rob PM & Jelkmann W. Theophylline and magnesium inhibit the contraction elicited with ciclosporin and angiotensin II in mesangial cell cultures. Nephron 1991; 57:94-98.
28. Pere A-K, lindgren L, Tuomainem P, Krogerus L, Rauhala P, Iaakso J, Karpanen H, Vapaatalo H, Ahonen J & Mervaala EMA. Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity. Kidney International 2000; 58:2462-2472.
29. Rao TKS. Acute renal failure syndromes in human immunodeficiency virus infection. Seminars in Nephrology 1998; 18:378-395.